help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on October 22, 2009
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2009-1500
This Article
Right arrow Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Valassi, E.
Right arrow Articles by Biller, B. M. K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valassi, E.
Right arrow Articles by Biller, B. M. K.

Submitted on July 14, 2009
Accepted on September 9, 2009

Concomitant Medication Use Can Confound Interpretation of the Combined Dexamethasone-Corticotropin Releasing Hormone Test in Cushing's Syndrome

Elena Valassi, Brooke Swearingen, Hang Lee, Lisa B. Nachtigall, Daniel A. Donoho, Anne Klibanski, and Beverly M. K. Biller*

Neuroendocrine Clinical Center (E.V., L.B.N., D.A.D., A.K., B.M.K.B.), Department of Neurosurgery (B.S.), and Biostatistics Center (H.L.), Massachusetts General Hospital and Harvard Medical School Boston, Massachusetts 02114

* To whom correspondence should be addressed. E-mail: bbiller{at}partners.org.

Context: The ability of combined dexamethasone-corticotropin releasing hormone (Dex-CRH) testing to distinguish pseudo-Cushing's syndrome (PCS) from Cushing's syndrome is controversial. One factor potentially impairing diagnostic efficacy is the concomitant use of commonly prescribed medications that may alter dexamethasone metabolism.

Objective: Our objective was to assess the diagnostic accuracy of the Dex-CRH test and evaluate the potential impact of concomitant drugs.

Design: The study was a retrospective one.

Participants: Participants included 101 patients [60 Cushing's disease (CD); 41 PCS] who underwent 112 Dex-CRH tests. Patients were divided into two groups, depending on use of medications potentially interfering with dexamethasone metabolism: 58 tests were classified as No Meds (32 CD; 26 PCS) and 54 as Meds (34 CD; 20 PCS). The latter group was further subdivided into patients taking one medication vs. those taking multiple medications.

Main Outcome Measures: Diagnostic accuracy of different serum cortisol and ACTH thresholds at baseline and 15 min after CRH injection was assessed.

Results: The specificity of a baseline post-low-dose-dexamethasone-suppressed test cortisol lower than 1.4 μg/dl (38 nmol/liter) was significantly higher in the No Meds vs. the Meds group (P = 0.014). Sensitivity and specificity using a post-CRH cortisol cutoff of 1.4 μg/dl (38 nmol/liter) were 93.1% (95% confidence interval = 88.4–97.8) and 92.3% (95% confidence interval = 87–97.6) in the No Meds group. The specificity of a cortisol lower than 1.4 μg/dl (38 nmol/l) at 15 min after CRH was significantly higher in patients taking only one medication vs. those on multidrug treatment (P < 0.05).

Conclusions: Medications commonly prescribed in hypercortisolemic patients undergoing Dex-CRH testing may contribute to the variable diagnostic accuracy of this test. Prospective studies to address this issue are needed.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society